Over 15 inherited diseases are caused by expansion of triplet-repeats. Friedreich ataxia (FRDA) patients are homozygous for an expanded GAA triplet-repeat sequence in intron 1 of the FXN gene. The expanded GAA triplet-repeat results in deficiency of FXN gene transcription, which is reversed via administration of histone deacetylase inhibitors indicating that transcriptional silencing is at least partially due to an epigenetic abnormality.
We found a severe depletion of the chromatin insulator protein CTCF (CCCTC-binding factor) in the 5′UTR of the FXN gene in FRDA, and coincident heterochromatin formation involving the +1 nucleosome via enrichment of H3K9me3 and recruitment of heterochromatin protein 1. We identified FAST-1 (FXN Antisense Transcript – 1), a novel antisense transcript that overlaps the CTCF binding site in the 5′UTR, which was expressed at higher levels in FRDA. The reciprocal relationship of deficient FXN transcript and higher levels of FAST-1 seen in FRDA was reproduced in normal cells via knockdown of CTCF.
CTCF depletion constitutes an epigenetic switch that results in increased antisense transcription, heterochromatin formation and transcriptional deficiency in FRDA. These findings provide a mechanistic basis for the transcriptional silencing of the FXN gene in FRDA, and broaden our understanding of disease pathogenesis in triplet-repeat diseases.
Citation: De Biase I, Chutake YK, Rindler PM, Bidichandani SI (2009) Epigenetic Silencing in Friedreich Ataxia Is Associated with Depletion of CTCF (CCCTC-Binding Factor) and Antisense Transcription. PLoS ONE 4(11): e7914. doi:10.1371/journal.pone.0007914
Editor: Amanda Ewart Toland, Ohio State University Medical Center, United States of America
Received: April 8, 2009; Accepted: October 22, 2009; Published: November 19, 2009
Copyright: © 2009 De Biase et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was made possible in part by grants from the National Institutes of Health (NINDS) and Muscular Dystrophy Association to S.I.B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Friedreich ataxia (FRDA), the most common inherited ataxia, is an autosomal recessive disease characterized by progressive sensory ataxia, cardiomyopathy, diabetes, and premature death . FRDA is most commonly caused by inheriting an expanded GAA triplet-repeat sequence in intron 1 of both copies of the FXN gene . The size of the expanded repeat tract can range from 66–1700 triplets, which results in a deficiency of FXN gene transcription , . This in turn causes a deficiency of the mitochondrial protein frataxin, which is essential for iron-sulfur cluster biogenesis, and thereby results in mitochondrial dysfunction .
Exactly how FXN transcriptional silencing is achieved in FRDA is not well understood, however recent evidence indicates that an epigenetic abnormality is an important underlying mechanism. In unrelated transgenic mouse experiments, the expanded GAA triplet-repeat sequence was found to be a source of position effect variegation (PEV) i.e., a source of heterochromatin spreading into adjacent euchromatin . Consistent with this observation, evidence of heterochromatin formation was found in the immediate vicinity of the expanded GAA triplet-repeat in cells from FRDA patients –. More importantly, histone deacetylase (HDAC) inhibitors resulted in partial reversal of the gene silencing in patient-derived cells , indicating that heterochromatin formation is an important underlying mechanism for the transcriptional deficiency in FRDA. However, heterochromatin formation has not been convincingly demonstrated in any region other than intron 1 of the FXN gene in cells of FRDA patients, and exactly how transcriptional silencing occurs is not fully understood.
Here, we report that FRDA patients have a severe depletion of the chromatin insulator protein CTCF (CCCTC-binding factor) in the 5′ untranslated sequence (5′UTR) of the FXN gene. We also found that CTCF depletion was associated with higher levels of an antisense transcript, and heterochromatin formation involving the critical +1 nucleosome in the vicinity of the transcription start site (TSS) of the FXN gene. Knockdown of CTCF reproduced the deficiency of FXN gene transcription, and higher levels of antisense transcription. Our data support the hypothesis that CTCF depletion in FRDA constitutes an epigenetic switch that results in heterochromatin formation and deficiency of FXN gene transcription.
CTCF Is Depleted in the 5′UTR of the FXN Gene in FRDA
Publicly available ChIP-on-CHIP data  revealed a single CTCF binding site in the FXN gene that maps in the 5′UTR (+154 to +173, relative to the most proximal TSS [TSS1]) (Fig. 1A). Electrophoretic mobility shift assay (EMSA) using the 5′UTR as a probe and HeLa nuclear extract showed a single shifted complex (Fig. 1B). This complex was competed away with an oligonucleotide probe containing the consensus CTCF-binding site, but not with a control probe containing a mutant CTCF-binding sequence (Fig. 1B), indicating that the shift was due to CTCF binding in the 5′UTR. Chromatin immunoprecipitation (ChIP) with anti-CTCF using fibroblast cell lines from two normal individuals showed considerable enrichment of CTCF in the 5′UTR of the FXN gene in vivo, which was comparable to that seen at the MYC locus, used as a positive control (Fig. 1C). Strikingly, the same ChIP assay performed with fibroblast cell lines from two FRDA patients, who were homozygous for expanded GAA triplet-repeat sequences in intron 1 of the FXN gene, showed four-fold reduced occupancy of CTCF in the 5′UTR (Fig. 1D). These data indicate that CTCF is depleted from the 5′UTR of the FXN gene in FRDA patients. Comparison of CTCF occupancy at the MYC locus, and at another CTCF binding site at the APBA1 (Amyloid beta A4 precursor protein-binding family A member 1) locus on chromosome 9q, in FRDA versus normal cell lines did not show a similar reduction, indicating that FRDA cells do not have a generalized defect of CTCF binding (Fig. S1). DNA methylation is known to interfere with CTCF binding , and there are two CpG dinucleotides associated with the CTCF binding site in the FXN 5′UTR. Given that FRDA patients have increased CpG methylation in intron 1 of the FXN gene , , we investigated if altered methylation in the 5′UTR was a possible mechanism for the depletion of CTCF. Bisulfite treatment, followed by sequencing of twelve individual clones from each of two FRDA and two control fibroblasts, did not show any alteration in methylation status at any of the nine CpG dinucleotides spanning the 5′UTR (including the two that overlap with the CTCF binding site), or in the first six CpG sites of exon 1. Furthermore, EMSA performed with HeLa nuclear extract and an in vitro methylated 5′UTR probe (methylation status of which was confirmed by bisulfite sequencing) showed the same major complex obtained with the unmethylated probe, which was competed away by excess cold unmethylated probe (Fig. S2), indicating that altered DNA methylation is unlikely to be the reason for CTCF depletion in the FXN 5′UTR in FRDA.
(A) Schematic representation of the relevant portion of the FXN gene showing the CTCF binding site in the 5′UTR, and the regions analyzed by EMSA and ChIP. All numbers are relative to TSS1. The region denoted as “Pro” is the portion of the promoter/5′UTR previously analyzed by other groups and shown not to have heterochromatin formation in FRDA , . (B) EMSA with HeLa nuclear extract showing a single complex (arrow) that was competed with excess cold probe, CTCF binding oligonucleotide, but not with a mutant CTCF oligonucleotide, indicating that CTCF binds in the FXN 5′UTR. (C) ChIP with anti-CTCF in fibroblasts from non-FRDA controls showing enrichment of CTCF in the FXN 5′UTR in vivo. The CTCF insulator (MYC-N) and a non-binding site (MYC-G) in the MYC gene were used as positive and negative controls for CTCF enrichment in vivo. The enrichment at the FXN 5′UTR is comparable to the MYC locus. The GAPDH fragment used to normalize the ChIP data did not show CTCF enrichment. (D) ChIP with anti-CTCF in fibroblasts from two non-FRDA control fibroblasts (CNTR) and two FRDA patients showed significantly less occupancy of CTCF in FRDA. The data are from two independent chromatin preparations, with each experiment done in triplicate. Error bars = s.e.m.; “*” = P<0.05; “***” = P<0.001.
Heterochromatin Formation Involving the +1 Nucleosome of the FXN Gene in FRDA
We hypothesized that in FRDA patients depletion of CTCF, a known chromatin insulator protein , would be associated with heterochromatin formation in the 5′UTR. Publicly available, genome-wide, nucleosome occupancy data (nucleosome occupancy super-track; UCSC genome browser –) showed that the +1 nucleosome of the FXN gene encompassed the CTCF binding site in the 5′UTR, which was preceded by a long nucleosome free region containing the three reported TSS's of the FXN gene (denoted as TSS1-3 in Fig. 1A). ChIP followed by quantitative PCR of the region spanning the +1 nucleosome showed significant enrichment of histone modifications characteristic of heterochromatin formation specifically in FRDA cell lines. We detected significant enrichment of H3K9me3 and H3K27me3 (Fig. 2A,B). H3K9me3 is known to recruit heterochromatin protein 1 (HP1) via interaction with the latter's chromodomain. Indeed, we also detected significant enrichment of HP1 (both α and γ subunits were tested and found to be enriched) in FRDA compared with normal fibroblasts (Fig. 2C,D). These data indicate that CTCF depletion in FRDA patients is associated with heterochromatin formation involving the +1 nucleosome of the FXN gene.
ChIP assays showing enrichment of (A) H3K9me3, (B) H3K27me3, and (C,D) heterochromatin protein 1 subunits HP-1α and HP-1γ, specifically in FRDA fibroblast cell lines versus non-FRDA controls (CNTR). All bars represent cumulative data from two fibroblast cell lines (FRDA or non-FRDA control), ChIP performed in triplicate, on two independent chromatin preparations. Error bars = s.e.m.; “*” = P<0.05; “**” = P<0.01.
FRDA Patients Have Higher Levels of FAST-1
As a potential mediator of heterochromatin formation, we searched for an antisense transcript overlapping with the 5′UTR of the FXN gene. Strand-specific RT-PCR was carried out with a primer located upstream of FXN TSS3 (Fig. 3A) and RNA from normal fibroblasts, which revealed an antisense transcript that overlapped with the CTCF binding site (Fig. 3A,B). We have named this novel transcript FAST-1 (FXN Antisense Transcript – 1). No such product was detected in a “no-RT” reaction or in a “RT” reaction without exogenous primers (Fig. 3B), indicating that this product was not amplified from contaminating DNA or via spurious endogenous priming. Sequencing of the isolated transcript showed that it was a perfect match to the antisense strand of FXN, and BLAST analysis of this sequence showed only a single hit (to the FXN locus), indicating that FAST-1 originates from the FXN locus. RT-PCR experiments indicated that FAST-1 overlaps with the FXN gene, including at least portions of intron 1, exon 1, the 5′UTR, and extends further upstream into the nucleosome free region and upstream of FXN TSS3 (until -343; Fig. 3A). It is presently unclear if the putative polyadenylation sequence located upstream of FXN TSS3 (−340; Fig. 3A) is utilized by FAST-1. A tag corresponding to FAST-1 was identified in a recent study of the human antisense transcriptome (position 70840691 on the “-” strand of chromosome 9 in the HCT116 cell line)  (Papadopoulos, personal communication), which maps close to the start of intron 1 of the FXN gene (Fig. 3A), and further substantiates the existence of FAST-1. FAST-1 contains an open reading frame which encodes a putative peptide of 154 amino acids (70840410 to 70840874 on the “-” strand of chromosome 9, which spans the antisense sequence tag isolated in ), with homology to two uncharacterized open reading frames in rice. The open reading frame extends from FXN intron 1, through exon 1, and ends in the 5′UTR, and includes the CTCF binding site (Fig. 3A). However, the importance of this open reading frame is unclear since it is intact in human and chimpanzee, but contains premature stop codons in orangutan, rhesus, and marmoset, and the translational initiation site does not show a Kozak consensus sequence.
(A, B) Strand-specific RT-PCR showed the presence of an antisense transcript that overlaps with the FXN gene. The transcript extends at least from FXN intron 1 to upstream of the FXN TSS. The solid line represents the part of the transcript (207-bp product in B) that we could amplify using one round of PCR (with FAST-F1 and FAST-R1; see Methods), and the dotted line denotes the extended transcript that we detected via nested PCR. The FAST-1 product was not detected in a no-RT control (RT-), or when the RT reaction was performed without any exogenous primers (RTp-). The diamond symbol represents a sequence tag corresponding to FAST-1, identified in the antisense transcriptome . The gray bar represents the extent of an open reading frame, and “pA” denotes a putative polyadenylation (pA) signal for FAST-1. All numbers are relative to TSS1. (C) Real-time RT-PCR (with FAST-F1 and FAST-R1) showed twice as much FAST-1 levels in FRDA cell lines versus non-FRDA controls (CNTR). The bars represent cumulative data from two fibroblast cell lines (FRDA or CNTR), RT-PCR in triplicate, from two independent experiments. Error bars = s.e.m.; “***” = P<0.001.
We hypothesized that FRDA patients would have higher levels of FAST-1, corresponding to the depletion of CTCF and heterochromatin formation in the FXN 5′UTR. Indeed, real-time RT-PCR to measure FAST-1 levels in FRDA versus normal fibroblasts revealed that patients had twice as much of this antisense transcript (Fig. 3C). It should be noted that our data are consistent with either actual overexpression of FAST-1, increased spreading of FAST-1 upstream beyond the CTCF binding site, or both.
CTCF Knockdown Reproduces the Deficiency of FXN Transcript and Higher Levels of FAST-1 Seen in FRDA Cells
In order to test if CTCF depletion is responsible for the deficiency of FXN transcript and higher levels of FAST-1, as is seen in FRDA patients, siRNA-mediated knockdown of CTCF was performed in fibroblasts. Western blot analysis and quantitative RT-PCR confirmed the global knockdown of CTCF (Fig. S3, S4), and a micro-ChIP assay  was used to confirm depletion of CTCF specifically in the 5′UTR of the FXN gene (Fig. S5). Real-time RT-PCR showed a significant reduction in the levels of FXN transcript in siRNA treated fibroblasts from normal individuals, but no further reduction was seen in FRDA cells (Fig. 4A). This effect was unrelated to the transfection protocol per se, since no such effect was seen with a scrambled sequence control siRNA (Fig. S3, S4, S5, S6). Furthermore, real-time RT-PCR showed a corresponding doubling of the levels of FAST-1 upon siRNA knockdown in normal fibroblasts (Fig. 4B). Indeed, FAST-1 levels in normal fibroblasts were equalized to the level seen in FRDA cells via knockdown of CTCF. CTCF knockdown in FRDA cells did not result in further increase in FAST-1 levels. These data indicate that depletion of CTCF in normal cells is capable of reproducing the reciprocal deficiency of FXN transcript and higher levels of FAST-1, and is comparable in scale to what is seen naturally in FRDA cells.
All bars represent cumulative data from two fibroblast cell lines (FRDA or CNTR), RT-PCR done in triplicate, from two independent experiments. Error bars = s.e.m.; “**” = P<0.01; “***” = P<0.001. (A) Real-time RT-PCR showed that knockdown of CTCF in normal fibroblasts (CNTR) resulted in significant reduction in levels of FXN transcript, which was similar to that seen in FRDA fibroblasts (the levels of FXN transcript in FRDA cells is similar to those reported previously , ). Knockdown of CTCF in FRDA cell lines seemed to further reduce FXN transcript levels but this was not statistically significant. (B) Real-time RT-PCR showed that knockdown of CTCF in normal fibroblasts (CNTR) resulted in significant increase in levels of FAST-1, which was similar to that seen in FRDA fibroblasts. Knockdown of CTCF in FRDA cells did not further increase FAST-1 levels, which remained around twice as high as in normal cells.
The expanded GAA triplet-repeat sequence results in deficiency of FXN transcript via at least two mechanisms: deficient transcriptional elongation through the expanded repeat tract , ,  and epigenetic silencing –. Previous studies detected evidence of heterochromatin formation in the immediate vicinity of the expanded GAA triplet-repeat in intron 1 in FRDA –, however, it has remained unclear how this results in transcriptional silencing of the FXN gene. Our data are consistent with the model that CTCF depletion in the 5′UTR of the FXN gene in FRDA patients results in reduced FXN transcription via heterochromatin formation involving the critical +1 nucleosome, which offers a plausible mechanism for transcriptional silencing of the FXN gene, and is consistent with the observed transcriptional reactivation via administration of HDAC inhibitors . It is interesting to note that previous unsuccessful attempts to detect heterochromatin formation in the upstream regions of the FXN gene in FRDA were directed to the nucleosome free region immediately upstream of TSS1 , ; the sequence we have analyzed here is ∼100 nucleotides downstream of this sequence, and represents the +1 nucleosome (Fig. 1A). The +1 nucleosome is an important regulator of transcription  and alteration of its chromatin organization in FRDA has the possibility of influencing FXN transcriptional initiation and/or elongation. It is also interesting to note that heterochromatin formation in the vicinity of the expanded GAA triplet-repeat in intron 1 of FRDA patients is different from what we have observed in the 5′UTR. The former is associated with increased CpG methylation at specific sites in intron 1, whereas we did not detect any alterations in DNA methylation in the 5′UTR. Instead, heterochromatin formation in the 5′UTR seems to be based on H3K9me3-mediated recruitment of HP1.
Antisense transcripts have been implicated in heterochromatin formation via H3K9me3 and subsequent recruitment of HP1 –. Most human genes are known to have transcripts that emanate from, and head upstream of, their transcription start sites –. However, these are technically not “antisense” transcripts since they do not overlap with sense transcripts. Nevertheless, ∼15% of genes are known to have bona fide antisense transcripts ,  that may serve to regulate the expression of their corresponding sense transcripts. The discovery of FAST-1 is therefore not surprising in itself, however, the detection of higher levels of FAST-1 in the region showing heterochromatin formation in FRDA patients offers a plausible mechanistic basis for the epigenetic abnormality involving the +1 nucleosome –. Moreover, since knockdown of CTCF in normal fibroblasts reproduced the increase in levels of FAST-1 seen in FRDA fibroblasts, it suggests that CTCF depletion is required for increased FAST-1 levels or spreading. Indeed, increased spreading, or level of expression, of antisense transcripts has been shown to induce epigenetic silencing of the corresponding “sense” gene. A genomic deletion involving an intervening transcriptional termination signal resulted in abnormal spreading of an antisense transcript into the human α-globin gene and resulted in transcriptional silencing associated with DNA hypermethylation . Furthermore, the microRNA-mediated transcriptional silencing via heterochromatin formation, which is well characterized in S. pombe, is also conserved in mammalian cells , and most likely results from targeting of the sense transcript, rather than the genomic DNA itself . Indeed, Yu et al.  directly demonstrated that mammalian cells are capable of establishing heterochromatin formation via overexpression of an antisense transcript. Therefore, taken together, our data support the model that CTCF depletion constitutes an epigenetic switch in FRDA that allows increased expression or spreading of FAST-1, heterochromatin formation involving the +1 nucleosome, and transcriptional silencing of the FXN gene (Fig. 5).
(A) In non-FRDA cells there is low level of FAST-1 (dotted arrow), normal occupancy of CTCF and no heterochromatin formation in the 5′UTR. (B) Our data are compatible with the following model in FRDA cells: CTCF is depleted from the 5′UTR, followed by increased levels (or spreading) of FAST-1 into the 5′UTR (arrow), which induces H3K9me3 and HP-1 mediated heterochromatin formation (filled pattern), leading to transcriptional silencing of the FXN gene.
CTCF, a multi zinc-finger protein, binds ∼15,000 sites in the human genome . Indeed, the site we identified in the FXN 5′UTR is one of ∼6,000 sites that are located in the vicinity of transcription start sites of human genes. CTCF is a chromatin insulator that acts by establishment of chromatin topological domains via CTCF-CTCF interactions, and tethering to the nucleolar surface via CTCF-nucleophosmin interactions. This higher-order chromatin organization is known to regulate gene expression via creation of boundaries in chromatin – such that they prevent (or facilitate) interactions between enhancers and promoter sequences (enhancer-blocking insulators), or by preventing the spread of heterochromatin (e.g. via PEV) by creating a barrier between active and silenced chromatin (barrier insulators). This higher-order organization afforded by chromatin insulators is an important regulator of normal gene expression –. Our data suggest various potential (non mutually-exclusive) ways by which CTCF depletion could result in heterochromatin formation and deficiency of FXN transcript. It is possible that a CTCF-mediated, enhancer-blocking insulator normally keeps FAST-1 expression low. Local depletion of CTCF in FRDA could disrupt this enhancer-blocking activity, allowing FAST-1 overexpression (as occurs in the paternal IGF2 allele at the imprinted H19-IGF2 locus). Another possibility is that CTCF depletion in the FXN 5′UTR could allow increased spreading of FAST-1 to upstream sequences. FAST-1 overexpression or increased spreading could result in heterochromatin formation and FXN gene silencing via H3K9me3 and recruitment of HP-1 –. Indeed, CTCF is known to limit the spread of an antisense transcript at the human DMPK locus . CTCF is displaced in the presence of very large expansions of a nearby CTG triplet-repeat sequence, resulting in spreading of antisense transcription and heterochromatin formation beyond their limited confines, leading to congenital myotonic dystrophy . Another possibility is that the depletion of CTCF in the 5′UTR could disrupt a CTCF-mediated topological segregation of the expanded GAA triplet-repeat, a known source of PEV , from the 5′UTR and TSS of the FXN gene. This would allow the upstream spreading of heterochromatin from the expanded GAA triplet-repeat in FRDA patients, thus resulting in FXN transcriptional deficiency.
It remains unclear as to how the expanded GAA triplet-repeat, the cause of FRDA , results in displacement of CTCF. Cohesin, which is essential for sister chromatid cohesion , often colocalizes with CTCF –. Cohesin also cooperates with CTCF in regulating gene expression , and is required for CTCF binding at some sites , . An intriguing possibility is that the expanded GAA triplet-repeat sequence, possibly via formation of a non-B DNA structure , , , may compromise the loading, binding, or stability of cohesin and thereby promote CTCF displacement. Another possibility, which cannot be ruled out presently, is that FAST-1 overexpression may itself displace CTCF from the 5′UTR, either directly or secondary to +1 nucleosomal modification and/or displacement. Indeed, lipopolysaccharide-induced overexpression of the chicken lysozyme gene is mediated by increased antisense transcription that results in repositioning of a nucleosome over the CTCF binding site leading to its eviction . The coincidence of the CTCF binding site in the FXN 5′UTR and the +1 nucleosome tends to support this type of mechanism, although our data did demonstrate that FAST-1 overexpression occurred as a result of CTCF deficiency.
The discovery that HDAC inhibitors result in reversal of the FXN transcriptional silencing has led to their use in currently ongoing clinical trials. Our findings provide a mechanistic basis for the transcriptional silencing of the FXN gene in Friedreich ataxia that is consistent with this response to HDAC inhibitors, and elucidate a rational basis for their action. Moreover, the identification of localized CTCF depletion and increased FAST-1 levels offer potential therapeutic targets for the specific reactivation of the transcriptionally silenced FXN gene in FRDA.
Materials and Methods
Fibroblasts from two healthy subjects (GM04503, GM07492) and two FRDA patients (GM03665, GM04078) were obtained from Coriell Cell Repository. Expanded GAA alleles for the two FRDA patients were 445 & 740 triplets (GM03665), and 345 & 470 triplets (GM04078). All experiments were performed with early passages of the four cell lines.
Electrophoretic Mobility Shift Assay
A 231-bp PCR fragment (position −222 to +9 relative to the initiation codon) containing the putative CTCF binding site in the 5′UTR of the FXN gene was used as the probe. The end-labeled probe was incubated with HeLa nuclear extract (5 µg; Millipore) for 40 minutes at room temperature in binding buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol, and poly dI-dC), and resolved on a 5% native polyacrylamide gel. Cold competition was performed using excess unlabeled probe, a CTCF consensus oligonucleotide (sc-2613; Santa Cruz), or a mutant CTCF oligonucleotide (sc-2614; Santa Cruz). Methylated probe for EMSA was generated via in vitro methylation using M.SssI CpG methyltransferase and S-adenosylmethionine (New England BioLabs).
Bisulfite Sequencing for Detection of CpG Methylation
200 ng of genomic DNA was treated using the EZ DNA Methylation-Direct Kit (Zymo Research) to convert unmethylated cytosines to uracil. PCR was performed using the following primer pairs: CTCF-meth-F1 5′-GCTCCGTCTAGATTGTGTATGTATTTATTTTTTAG-3′ and CTCF-meth-R1 5′-GATGCGCTGCAGAAAATAAAACCAACTCTACC-3′ followed by nested PCR with primers: CTCF-meth-F2 5′-GCTCCGTCTAGAGGTTGTATTTCGTGTTTTGT-3′ and CTCF-meth-R2 5′-GATGCGCTGCAGCTAAACCTAAACTAAACTAAATAAC-3′. The XbaI and PstI sites in the forward and reverse primers, respectively, were used to clone the PCR products into pUC19. Twelve clones were sequenced for each DNA sample. Cytosine to uracil conversion was complete at all non CpG sites.
Chromatin Immunoprecipitation (ChIP)
We used the ChIP-IT Express kit (Active Motif). Immunoprecipitations were performed overnight at 4°C using anti-CTCF (Millipore 07-729), anti-H3K9me3 (Millipore 17-625), anti-H3K27me3 (Millipore 07-449), anti-HP1α (Millipore 07-346), or anti-HP1γ (Millipore 07-332). The immunoprecipitated DNA and the input DNA were analyzed by real-time PCR using the ΔΔCt method on the Eppendorf RealPlex-4 Mastercycler with Power SYBR Green PCR Mastermix (Applied Biosystems) and the following primers:
FXN-ChIP-forward 5′-TCCTGAGGTCTAACCTCTAGCTGC-3′ and
GAPDH-ChIP-forward 5′-CCTCCCGCTTCGCTCTCT-3′ and
Each value of immunoprecipitated DNA, normalized to GAPDH, was further normalized to the corresponding input DNA. All ChIP experiments, which were performed in triplicate, were done using two independent chromatin preparations. All data are from the two FRDA cell lines combined versus the two normal controls combined. The human CTCF insulator (MYC-N) and a non-binding site (MYC-G) in the MYC gene were used as positive and negative controls for CTCF binding . The region of GAPDH used to normalize the ChIP data was confirmed to not enrich CTCF by comparing it with another region of the GAPDH gene located far away from any known CTCF binding sites (using the following primers: 5′-TACTAGCGGTTTTACGGGCG-3′ and 5′-TCGAACAGGAGGAGCAGAGAGCGA-3′). CTCF enrichment at the APBA1 locus on chromosome 9 was tested with primers: 5′-CCTCAATCGCCTGGGAATCT-3′ and 5′-GCCCTCCCCAGCAGACA-3′. Micro-ChIP was used to test the depletion of CTCF specifically in the FXN gene. This was essentially performed as previously described . The only modifications we implemented included the use of 25,000 cells and optimization of the sonication step to yield a modal sheared chromatin size of ∼500 bp.
Total RNA was isolated with TriPure (Roche), and cDNA was synthesized using the QuantiTect reverse transcription kit (Qiagen). Relative transcript levels were measured by real-time PCR as above, and normalized to HPRT. FXN transcript levels were detected as previously described . Detection of FAST-1 was accomplished by reverse transcription using a strand-specific primer (FAST-RT: 5′- CCAAGCAGCCTCAATTTGTG-3′). PCR was performed with FAST-F1 (5′-GTGGGGGAGCAGCTAGAGG-3′) and FAST-R1 (5′-CACTTCCCAGCAAGACAGC-3′) (note: “F” and “R” designations are in the FAST-1 orientation). PCR for FAST-1 was performed using either Taq DNA polymerase (Roche) or the Power SYBR Green PCR Mastermix (Applied Biosystems), and 35 cycles of 30 s at 95°C, 30 s at 62°C, and 30 s at 70°C. Relative FAST-1 levels were quantified by real-time PCR (as above), and expression levels were normalized to HPRT. Statistical analysis was performed with triplicate data from two independent experiments.
siRNA Knockdown of CTCF
Stealth RNAi for CTCF (Invitrogen; 6 µg) was used to transfect cells in 6-well plates using Lipofectamine 2000 (Invitrogen). Stealth RNAi Negative Universal Control (Invitrogen) was used as the scrambled sequence control. Cells were harvested 48 hr post-transfection. CTCF knockdown was confirmed using quantitative RT-PCR (with primers described in ) and western blot analysis with anti-CTCF antibody (Millipore 07-729). β-actin (Abcam 8227) was used as the loading control for the western blot analysis.
FRDA cells do not have a generalized defect of CTCF binding. ChIP with anti-CTCF in fibroblasts from FRDA and non-FRDA controls (CNTR) showed no reduction in enrichment of CTCF at the MYC-N insulator and the APBA1 (Amyloid beta A4 precursor protein-binding family A member 1) locus on chromosome 9q in vivo. Whereas the APBA1 locus showed no difference, the MYC-N site showed a slight increase in FRDA cells, the biological significance of which is unclear.
(0.85 MB TIF)
CTCF binds in vitro to the methylated FXN 5UTR. EMSA performed with HeLa nuclear extract and an in vitro methylated 5′UTR probe (methylation status of which was confirmed by bisulfite sequencing) showed a similar major complex as with the unmethylated probe. This complex was competed away by excess cold unmethylated probe, indicating that CTCF binds the 5′UTR irrespective of methylation status and that altered DNA methylation is unlikely to be the reason for CTCF depletion in the FXN 5′UTR in FRDA.
(0.64 MB TIF)
Western blot analysis showing siRNA mediated knockdown of CTCF protein. Fibroblasts from non-FRDA controls, either untransfected (UT), or treated with scrambled control siRNA (SC) or with a specific CTCF siRNA are shown. Western blot analysis with anti-CTCF and anti β-actin antibodies showed reduction of CTCF protein specifically in cells treated with CTCF siRNA.
(0.19 MB TIF)
Quantitative RT-PCR analysis showing siRNA mediated knockdown of CTCF transcript. Fibroblasts from non-FRDA controls, either untransfected (UT), or treated with scrambled control siRNA (SC) or with a specific CTCF siRNA are shown. Quantitative RT-PCR analysis of relative CTCF transcript levels (normalized to HPRT) showed reduction of CTCF transcript specifically in cells treated with CTCF siRNA. Error bars = s.e.m.; “*” = P<0.05.
(0.57 MB TIF)
CTCF knockdown results in depletion of CTCF at the FXN locus. Micro-ChIP assay performed on non-FRDA fibroblasts, either untransfected (UT) or treated with scrambled control siRNA (SC) or specific CTCF siRNA showed reduced CTCF occupancy at the FXN locus specifically in cells treated with CTCF siRNA. Error bars = s.e.m.; “*” = P<0.05.
(0.57 MB TIF)
CTCF knockdown results in deficiency of FXN transcript. Quantitative RT-PCR performed on non-FRDA fibroblasts, either untransfected (UT) or treated with scrambled control siRNA (SC) or specific CTCF siRNA showed reduced levels of FXN transcript (normalized to HPRT) specifically in cells treated with CTCF siRNA. Error bars = s.e.m.; “*” = P<0.05.
(0.57 MB TIF)
Conceived and designed the experiments: IDB YC PR SB. Performed the experiments: IDB YC PR. Analyzed the data: IDB YC PR SB. Contributed reagents/materials/analysis tools: SB. Wrote the paper: IDB SB.
- 1. Pandolfo M (2008) Friedreich Ataxia. Arch Neurol 65: 1296–1303.
- 2. Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423–1427.
- 3. Bidichandani SI, Ashizawa T, Patel PI (1998) The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62: 111–121.
- 4. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, et al. (2004) Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 75: 1061–1063.
- 5. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R (2003) DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422: 909–913.
- 6. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, et al. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2: 551–558.
- 7. Greene E, Mahishi L, Entezam A, Kumari D, Usdin K (2007) Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 35: 3383–3390.
- 8. Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, et al. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17: 735–746.
- 9. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylation in the human genome. Cell 129: 823–837.
- 10. Filippova GN (2008) Genetics and epigenetics of the multifunctional protein CTCF. Curr Top Dev Biol 80: 337–360.
- 11. Ozsolak F, Song JS, Liu XS, Fisher DE (2007) High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol 25: 244–8.
- 12. Dennis JH, Fan HY, Reynolds SM, Yuan G, Meldrim JC, et al. (2007) Independent and complementary methods for large-scale structural analysis of mammalian chromatin. Genome Res 17: 928–39.
- 13. Gupta S, Dennis J, Thurman RE, Kingston R, Stamatoyannopoulos JA, et al. (2008) Predicting human nucleosome occupancy from primary sequence. PLoS Comput Biol 4(8): e1000134.
- 14. He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW (2008) The antisense transcriptomes of human cells. Science 322: 1855–1857.
- 15. Dahl JA, Collas P (2008) A rapid micro chromatin immunoprecipitation assay (μChIP). Nature Protocols 3: 1032–1045.
- 16. Ohshima K, Montermini L, Wells RD, Pandolfo M (1998) Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 273: 14588–95.
- 17. Burnett R, Melander C, Puckett JW, Son LS, Wells RD, et al. (2006) DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci USA 103: 11497–502.
- 18. Jiang C, Pugh BF (2009) Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet 10: 161–72.
- 19. Grewal SI, Jia S (2007) Heterochromatin revisited. Nat Rev Genet 8: 35–46.
- 20. Grewal SI, Elgin SC (2007) Transcription and RNA interference in the formation of heterochromatin. Nature 447: 399–406.
- 21. Iida T, Nakayama J, Moazed D (2008) siRNA-mediated heterochromatin establishment requires HP1 and is associated with antisense transcription. Mol Cell 1: 178–189.
- 22. Core LJ, Waterfall JJ, Lis JT (2008) Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322: 1845–1848.
- 23. Seila AC, Calabrese JM, Levine SS, Yeo GW, Rahl PB, et al. (2008) Divergent transcription from active promoters. Science 322: 1849–1851.
- 24. Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen MS, et al. (2008) RNA exosome depletion reveals transcription upstream of active human promoters. Science 322: 1851–1854.
- 25. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, et al. (2007) RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316: 1484–1488.
- 26. Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, et al. (2003) Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 34: 157–65.
- 27. Kim DH, Saetrom P, Snøve O Jr, Rossi JJ (2008) MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A 105: 16230–5.
- 28. Han J, Kim D, Morris KV (2007) Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells. Proc Natl Acad Sci U S A 104: 12422–7.
- 29. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, et al. (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451: 202–6.
- 30. Gaszner M, Felsenfeld G (2006) Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet 7: 703–713.
- 31. Bushey AM, Dorman ER, Corces VG (2008) Chromatin insulators: regulatory mechanisms and epigenetic inheritance. Mol Cell 32: 1–9.
- 32. Lunyak VV (2008) Boundaries. Boundaries…Boundaries??? Curr Opin Cell Biol 20: 281–287.
- 33. Cho DH, Thienes CP, Mahoney SE, Analau E, Filippova GN, et al. (2005) Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 20: 483–9.
- 34. Peters JM, Schmitz J, Tedeschi A (2008) The cohesin complex and its roles in chromosome biology. Genes Dev 22: 3089–114.
- 35. Parelho V, Hadjur S, Spivakov M, Leleu M, Sauer S, et al. (2008) Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 132: 422–433.
- 36. Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, et al. (2008) Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature 451: 796–801.
- 37. Rubio ED, Reiss DJ, Welcsh PL, Disteche CM, Filippova GN, et al. (2008) CTCF physically links cohesin to chromatin. Proc Natl Acad Sci U S A 105: 8309–8314.
- 38. Wendt KS, Peters JM (2009) How cohesin and CTCF cooperate in regulating gene expression. Chromosome Res 17: 201–14.
- 39. Sakamoto N, Chastain PD, Parniewski P, Ohshima K, Pandolfo M, et al. (1999) Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. Mol Cell 3: 465–75.
- 40. Lefevre P, Witham J, Lacroix CE, Cockerill PN, Bonifer C (2008) The LPS-induced transcriptional upregulation of the chicken lysozyme locus involves CTCF eviction and noncoding RNA transcription. Mol Cell 32: 129–39.
- 41. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, et al. (2007) Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 35: 7372–7388.